Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

antibody (1)

    displaying 1 - 4 records in total 4
    records per page




    New onset of Myasthenia Gravis MESHD in a patient with COVID-19: A novel case report and literature review

    Authors: Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan

    doi:10.21203/rs.3.rs-77694/v1 Date: 2020-09-14 Source: ResearchSquare

    The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China in December, 2019. The most striking manifestation is atypical pneumonia HP pneumonia MESHD and respiratory complications MESHD, however various neurological manifestations are now well recognized. Currently, there have been a very few case reports in regards to COVID-19 in patients with known history of myasthenia gravis MESHD. Myasthenia gravis MESHD ( MG MESHD) causes muscle weakness HP muscle weakness MESHD, especially respiratory muscles in high-risk COVID-19 patients that can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis MESHD following COVID-19, likely due to the involvement of the respiratory apparatus and from use of immunosuppressive medication. We report a first case MG MESHD developing secondary to COVID-19 infection MESHD in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough HP, fever HP fever MESHD, diarrhea HP diarrhea MESHD and was found to be positive for COVID-19 via nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies SERO against Acetylcholine receptor (AchR).COVID-19 is known to cause release of inflammatory cytokines leading to immune-mediated damage. MG MESHD is an immune-mediated disorder caused due to molecular mimicry and autoantibodies against the neuromuscular junction. 

    Association between autoimmune diseases MESHD and COVID-19 as assessed in both a test-negative case-control and population case-control design

    Authors: Rossella Murtas; Anita Andreano; Federico Gervasi; Davide Guido; David Consolazio; Sara Tunesi; Laura Andreoni; Maria Teresa Greco; Maria Elena Gattoni; Monica Sandrini; Antonio Riussi; Antonio Giampiero Russo

    doi:10.21203/rs.3.rs-58948/v1 Date: 2020-08-13 Source: ResearchSquare

    Background: COVID-19 epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19. Among those, emerged the notion that people suffering from autoimmune diseases MESHD ( AIDs MESHD) have a higher risk of SARS-CoV-2 infection MESHD. Methods: The cohort included all COVID-19 cases residents in the Agency for Health Protection (AHP) of Milan that, from the beginning of the outbreak, developed a web-based platform that traced TRANS positive and negative cases as well as related contacts. AIDs MESHD subjects were defined ad having one the following autoimmune disease MESHD: rheumatoid arthritis HP rheumatoid arthritis MESHD, systemic lupus erythematosus HP systemic lupus erythematosus MESHD, systemic sclerosis MESHD, Sjogren disease, ankylosing spondylitis MESHD, myasthenia gravis MESHD, Hashimoto's disease MESHD, acquired autoimmune hemolytic anemia HP autoimmune hemolytic anemia MESHD, and psoriatic arthritis MESHD arthritis HP. To investigate whether AID subjects are at increased risk of SARS-CoV-2 infection MESHD, and whether they have worse prognosis than AIDs MESHD-free subjects once infected, we performed a combined analysis of a test-negative design case-control study, a case-control with test-positive as cases, and one with test-negative as cases (CC-NEG). Results: During the outbreak, the Milan AHP endured, up to April 27th 2020, 20,364 test-positive and 34,697 test-negative subjects. We found no association between AIDs MESHD and being positive to COVID-19, but a statistically significant association between AIDs MESHD and being negative to COVID-19 in the CC-NEG. If, as likely, test-negative subjects underwent testing because of respiratory infection MESHD symptoms, these results imply that autoimmune diseases MESHD may be a risk factor for respiratory infections MESHD in general (including COVID-19), but they are not a specific risk factor for COVID-19. Furthermore, when infected by SARS-CoV-2, AIDs MESHD subjects did not have a worse prognosis compared to non- AIDs MESHD subjects. Results highlighted a potential unbalance in the testing campaign, which may be correlated to the characteristics of the tested person, leading specific frail population to be particularly tested.Conclusions: Lack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases MESHD.

    Management of Myasthenia Gravis MESHD During COVID-19 Pandemic

    Authors: Xingxing Wu; Jiang Yuan; Md Rezaul Karim; Yun-Fu Wang

    id:10.20944/preprints202006.0074.v1 Date: 2020-06-07 Source: Preprints.org

    The outbreak of COVID-19 has brought unprecedented risks and challenges to everyone in the world. Myasthenia gravis MESHD is an autoimmune disease MESHD of the nervous system. Infection can worsen it and cause severe symptoms such as myasthenia crisis MESHD and respiratory failure HP respiratory failure MESHD. At present, the pandemic of COVID-19 may promote the aggravation of patients with MG. This article focuses on the respiratory management of MG patients during the epidemic of COVID-19.

    The impact of COVID-19 epidemic on adult TRANS Myasthenia Gravis MESHD patients

    Authors: Yuyao Peng; Zhibin Li; Qiuming Zeng; Huan Yang

    doi:10.21203/rs.3.rs-20366/v1 Date: 2020-03-30 Source: ResearchSquare

    Objects: To investigate the impact of COVID-19 epidemic on adult TRANS myasthenia gravis MESHD ( MG MESHD) patients, in order to provide better medical advice for special patient population during the quarantine period.Methods: Adult TRANS MG MESHD patients were randomly recruited to participate. The survey consisted of self-designed questionnaires and the revised 15-item Myasthenia Gravis MESHD Quality of Life Questionnaire (MGQOL15r). Participation was strictly voluntary and remained anonymous.Results: A total of 214 adult TRANS MG MESHD patients (84 males TRANS and 130 females TRANS) gave valid replies. There were 49.53% patients reported they had the fear of COVID-19 outbreak at different levels. And female TRANS patients had a significant higher level of fear to COVID outbreak (p=0.009). It was found that the adult TRANS MG MESHD patients are more likely to be influenced by the COVID-19 epidemic compared to the general population. During the COVID-19 outbreak, 36.45% patients reported they got an improvement of MG disease MESHD severity. 57.01% patients reported they felt no change. 6.54% patients reported their condition got worse. The average of MGQOL15r score was 7.38±6.22. The higher level of the fear of COVID-19 outbreak, the higher score of MGQOL15r (p=0.029), the poorer quality of life. 96.73% patients hoped the specialist physicians could provide online consult. In addition, 64.95% patients would go to the tertiary hospital without hesitation if the Outpatients Department was opened even during the COVID-19 epidemic.Conclusions: The COVID-19 epidemic has significant impact on the quality of life and psychological status in the adult TRANS MG MESHD patients. Compared to the general population, the adult TRANS MG MESHD patients are more likely to be influenced by the COVID-19 epidemic. Hence, it is important for health care organizations to provide professional therapeutic advice and psychosocial support in time.*, Contributed to this work equally.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.